69 229

Cited 7 times in

High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study.

Authors
Bang, SM; Cho, EK; Suh, C; Yoon, SS; Seong, CM; Cho, KS; Kang, YG; Park, S; Ahn, MJ; Park, YS; Oh, D; Kim, HC; Jung, CW; Kim, S; Lee, JH
Citation
Journal of Korean medical science, 18(5):673-678, 2003
Journal Title
Journal of Korean medical science
ISSN
1011-89341598-6357
Abstract
We conducted a phase II multicenter trial to estimate the response and survival of patients with newly diagnosed multiple myeloma to high dose melphalan therapy followed by autologous peripheral blood stem cell transplantation. Eligible patients who had undergone induction with vincristine, adriamycin and dexamethasone (VAD) should have adequate cardiac, pulmonary and renal function (creatinine <2 mg/dL). Melphalan at 200 mg/m2 was used as a conditioning regimen. Eighty patients were enrolled from 13 centers. The median age of the patients was 53 yr (range; 20 to 68 yr). The initial stage was IA/IIA/IIB/IIIA/IIIB in 3/8/1/54/14 patients, respectively. Beta2-microglobulin, CRP and LDH were increased in 74, 42 and 34% of the patients examined. Cytogenetic data were available in 30 patients, and 6 patients showed numeric or structural abnormalities. Two therapy-related mortalities occurred from infection. Among the 78 evaluable patients, CR/PR/MR/NC/PD were achieved in 48/26/2/1/1 patients, respectively. After a median follow-up of 30 months, the median overall and event-free survivals were 66 months (95% CI: 20-112) and 24 months (95% CI: 18-29), respectively. This study verifies the efficacy and feasibility of high dose melphalan therapy with autologous stem cell transplantation in newly diagnosed multiple myeloma.
MeSH terms
AdultAgedAntigens, CD34/biosynthesisAntineoplastic Agents, Alkylating/therapeutic use*C-Reactive Protein/biosynthesisCell SurvivalCombined Modality TherapyCytogeneticsDisease-Free SurvivalFemaleHumansKoreaL-Lactate Dehydrogenase/biosynthesisMaleMelphalan/therapeutic use*Middle AgedMultiple Myeloma/therapy*Peripheral Blood Stem Cell Transplantation/methods*Time FactorsTransplantation, Autologous/methods*beta 2-Microglobulin/blood
DOI
10.3346/jkms.2003.18.5.673
PMID
14555819
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
AJOU Authors
김, 효철
Full Text Link
Files in This Item:
jkms-18-673-678.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse